Is Bharat Parenter. overvalued or undervalued?

As of August 9, 2024, Bharat Parenterals Ltd. is considered risky and overvalued, with alarming financial metrics such as a PE ratio of -73.55 and an EV to EBITDA ratio of 385.93, despite recent stock performance outpacing the Sensex.

As of 9 August 2024, Bharat Parenterals Ltd. has moved from a valuation grade of very expensive to risky, indicating a significant shift in its perceived value. The company is currently deemed overvalued, particularly highlighted by its PE ratio of -73.55 and an EV to EBITDA ratio of 385.93, which are both alarming figures suggesting substantial concerns regarding profitability and valuation metrics. Additionally, the Price to Book Value stands at 2.81, further reinforcing the notion of overvaluation.<BR><BR>In comparison to its peers, Bharat Parenterals Ltd. shows a stark contrast; for instance, its PE ratio is significantly worse than the industry average, and the EV to EBITDA ratio is exceedingly high compared to typical benchmarks. The company's recent stock performance has outpaced the Sensex over the past week and month, with returns of 9.29% and 24.85% respectively, but this does not mitigate the underlying valuation concerns. Overall, the financial metrics indicate that Bharat Parenterals Ltd. is not only risky but also overvalued in the current market landscape.

how big is Bharat Parenter.?

As of Jun 06, Bharat Parenterals Ltd has a market capitalization of 910.00 Cr and reported net sales of 340.38 Cr with a net profit of -12.62 Cr over the latest four quarters. Shareholder's funds are 197.27 Cr, and total assets are valued at 503.71 Cr as of Mar'24.

Market Cap: Bharat Parenterals Ltd has a market capitalization of 910.00 Cr and is classified as a Micro Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 340.38 Cr. The sum of Net Profit for the same period is -12.62 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending Mar'24. The Shareholder's Funds amount to 197.27 Cr, and the Total Assets are valued at 503.71 Cr.

What does Bharat Parenter. do?

Bharat Parenterals Ltd. manufactures drugs, pharmaceutical formulations, and ayurvedic products, operating as a Micro Cap company with a market cap of Rs 910 Cr. As of March 2025, it reported net sales of 104 Cr and a net loss of 5 Cr.

Overview: <BR>Bharat Parenterals Ltd. is engaged in the manufacturing of drugs, pharmaceutical formulations, and ayurvedic products within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Bharat Parenterals Ltd. was incorporated in September 1992 in Gujarat. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 104 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -5 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 910 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.07% <BR>Debt-Equity: 0.36 <BR>Return on Equity: -3.82% <BR>Price to Book: 2.75<BR><BR>Contact Details: <BR>Address: Survey No 144 & 146 Haripura, Jarod Samlaya Road Tal Savli Vadodara Gujarat : 391520 <BR>Tel: 91-2667-251679 <BR>Email: cs@bplindia.in/info@bplindia.in <BR>Website: http://www.bplindia.in

Has Bharat Parenter. declared dividend?

Bharat Parenterals Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of June 25, 2024. Recent total returns show a -22.1% return over the last 6 months, while longer-term returns have been more favorable, with a total return of 396.85% over the past 5 years.

Bharat Parenterals Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 25 Jun 24<BR><BR>Dividend Yield: 0.07%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.1%, with a dividend return of 0%, resulting in a total return of -22.1%.<BR><BR>Over the past year, the price return was -2.33%, the dividend return was 0.07%, leading to a total return of -2.26%.<BR><BR>In the 2-year period, the price return was 262.84%, the dividend return was 0.45%, culminating in a total return of 263.29%.<BR><BR>For the 3-year period, the price return stood at 273.76%, with a dividend return of 0.53%, resulting in a total return of 274.29%.<BR><BR>In the 4-year period, the price return was 200.0%, the dividend return was 0.47%, leading to a total return of 200.47%.<BR><BR>Over the last 5 years, the price return was 396.26%, with a dividend return of 0.59%, resulting in a total return of 396.85%.<BR><BR>Overall, Bharat Parenterals Ltd has declared a dividend, but the recent total returns indicate significant fluctuations, particularly in the short term, while longer-term returns have been more favorable.

Who are the peers of the Bharat Parenter.?

Bharat Parenter's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Shree Ganesh Rem, Kilitch Drugs, NGL Fine Chem, Nectar Lifesci, and Sakar Healthcare. In terms of management risk, growth, and capital structure, Bharat Parenter ranks average compared to its peers.

Peers: The peers of Bharat Parenter. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Shree Ganesh Rem, Kilitch Drugs, NGL Fine Chem, Nectar Lifesci., and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Bharat Parenter., Shree Ganesh Rem, and Sakar Healthcare. Below Average management risk is noted for Kilitch Drugs, NGL Fine Chem, and Nectar Lifesci. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is seen at Shree Ganesh Rem and Bharat Parenter., and Below Average growth is reported for Divi's Lab., Torrent Pharma, Kilitch Drugs, NGL Fine Chem, and Nectar Lifesci. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, and NGL Fine Chem, while Average capital structure is noted for Bharat Parenter. and Sakar Healthcare, and Good capital structure is observed at Torrent Pharma and Kilitch Drugs.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while NGL Fine Chem has the lowest at -52.32%. Bharat Parenter.'s own 1-year return is -8.58%, which is higher than NGL Fine Chem's but lower than Divi's Lab.'s. Additionally, peers such as NGL Fine Chem and Nectar Lifesci. have negative six-month returns.

Who are in the management team of Bharat Parenter.?

As of March 2022, the management team of Bharat Parenter includes Bharat Kumar R Desai (Managing Director), Hemang Jayendrabhai Shah, Shaileshkumar Ghabhawala, Sanjay Shah (Directors), and Zankhana Sheth, Mukesh Patel (Independent Directors). They oversee the company's operations and strategic direction.

As of March 2022, the management team of Bharat Parenter includes the following individuals:<BR><BR>1. Bharat Kumar R Desai - Managing Director<BR>2. Hemang Jayendrabhai Shah - Director<BR>3. Shaileshkumar Ghabhawala - Director<BR>4. Zankhana Sheth - Independent Director<BR>5. Mukesh Patel - Independent Director<BR>6. Sanjay Shah - Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the top shareholders of the Bharat Parenter.?

The top shareholder of Bharat Parenter is Desai Shares And Stock Private Limited, holding 39.63%. Other notable shareholders include Asoj Soft Caps Pvt Ltd at 4.94% and individual investors with a collective stake of 19.31%.

The top shareholders of Bharat Parenter include Desai Shares And Stock Private Limited, which holds the highest promoter stake at 39.63%. The company has no pledged promoter holdings, and there is one foreign institutional investor (FII) holding 0.11%. The highest public shareholder is Asoj Soft Caps Pvt Ltd, with a stake of 4.94%. Additionally, individual investors collectively hold 19.31% of the company's shares.

Are Bharat Parenter. latest results good or bad?

Bharat Parenterals' latest results show strong sales growth with net sales up 53.32% year-on-year, but significant losses in profit, with a Profit Before Tax of Rs -10.23 crore, indicate serious financial challenges. Overall, the results reflect a mix of positive sales performance and concerning profitability issues.

Bharat Parenterals' latest results present a mixed picture. On the positive side, the company achieved net sales of Rs 103.98 crore for the quarter ending March 2025, marking a substantial year-on-year growth of 53.32%. This is the highest quarterly sales figure in the last five quarters, indicating a strong sales trend. Additionally, the improvement in the Debtors Turnover Ratio to 1.98 times suggests that the company is managing its receivables more effectively.<BR><BR>However, the financial performance also highlights significant challenges. The Profit Before Tax (PBT) fell sharply to Rs -10.23 crore, a decline of 155.75% year-on-year, while the Profit After Tax (PAT) dropped to Rs -4.73 crore, which is a staggering decrease of 1476.7% year-on-year. The increase in interest expenses to Rs 3.94 crore, the highest in five quarters, points to rising borrowing costs that could be impacting profitability.<BR><BR>Overall, while the sales growth is encouraging, the substantial losses in profit and rising costs indicate that the company is facing considerable financial difficulties. Therefore, the results can be viewed as a mix of good sales performance but concerning profitability issues.

When is the next results date for Bharat Parenter.?

Bharat Parenter is scheduled to declare its results on 12 November 2025.

Bharat Parenter is scheduled to declare its results on 12 November 2025.

How has been the historical performance of Bharat Parenter.?

Bharat Parenter has experienced significant revenue growth, with net sales rising from INR 204.64 crore in March 2021 to INR 340.38 crore in March 2025. However, rising costs have led to declining profitability, resulting in a net loss of -INR 12.63 crore in March 2025.

Answer:<BR>The historical performance of Bharat Parenter shows significant fluctuations in key financial metrics over the years, culminating in a challenging fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Bharat Parenter's net sales have shown a steady increase from INR 204.64 crore in March 2021 to INR 340.38 crore in March 2025, reflecting a strong growth trajectory. However, total operating income followed a similar trend, reaching INR 340.38 crore in March 2025, up from INR 261.22 crore in March 2024. Despite this growth in revenue, the company faced rising raw material costs, which increased from INR 127.13 crore in March 2021 to INR 178.17 crore in March 2025. Consequently, total expenditure also rose significantly, leading to an operating profit (PBDIT) of only INR 2.70 crore in March 2025, a sharp decline from INR 27.08 crore in March 2024. This decline in profitability is further highlighted by a profit before tax of -INR 33.95 crore in March 2025, compared to a profit of INR 18.72 crore in March 2024. The net profit also turned negative, recording -INR 12.63 crore in March 2025, down from a profit of INR 14.51 crore in March 2024. On the balance sheet, total liabilities increased to INR 647.70 crore in March 2025 from INR 503.93 crore in March 2024, while total assets rose to INR 647.70 crore, indicating a growing leverage position. Cash flow from operating activities turned negative at -INR 4.00 crore in March 2024, contrasting with the previous year's positive cash flow. Overall, while Bharat Parenter has achieved revenue growth, it has struggled with profitability and rising costs, leading to a challenging financial position in recent years.

Should I buy, sell or hold Bharat Parenter.?

Which are the latest news on Bharat Parenter.?

Why is Bharat Parenter. falling/rising?

As of 04-Dec, Bharat Parenterals Ltd's stock price is Rs 1,162.00, reflecting a 1.48% decrease after a trend reversal. The stock has underperformed its sector and shows significant declines over the past month and year, indicating a bearish trend.

As of 04-Dec, Bharat Parenterals Ltd's stock price is falling, currently at Rs 1,162.00, which reflects a decrease of Rs 17.45 or 1.48%. This decline follows a trend reversal after four consecutive days of gains. The stock has underperformed its sector by 1.77% today and reached an intraday low of Rs 1,141.25, marking a drop of 3.24%. <BR><BR>Additionally, the stock's performance over the past month shows a decline of 4.94%, contrasting with a 2.16% increase in the Sensex. Year-to-date, Bharat Parenterals has experienced a significant drop of 20.83%, while the Sensex has risen by 9.12%. The stock's long-term performance also indicates a downward trend, with a 32.88% decrease over the past year compared to a 5.32% increase in the benchmark index.<BR><BR>Investor participation appears to be declining, as evidenced by a 6.65% drop in delivery volume on December 3rd compared to the five-day average. Furthermore, while the stock is trading above its 5-day and 20-day moving averages, it remains below the 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Overall, these factors contribute to the current decline in Bharat Parenterals Ltd's stock price.

Is Bharat Parenter. technically bullish or bearish?

As of December 4, 2025, Bharat Parenter's technical outlook is bearish, indicated by a bearish MACD, moving averages, and KST, along with mildly bearish Bollinger Bands, suggesting a consolidation phase without a clear trend.

As of 4 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly chart, bearish moving averages on the daily chart, and a bearish KST on the weekly chart. Additionally, Bollinger Bands are indicating a mildly bearish trend on both weekly and monthly time frames. The lack of signals from the RSI and Dow Theory suggests a consolidation phase without a clear trend. Overall, the technical outlook for Bharat Parenter is bearish.